Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2019

01-05-2019 | Pathology | Endocrine Tumors

A Population-Based Study on NIFTP Incidence and Survival: Is NIFTP Really a “Benign” Disease?

Authors: Antoine Eskander, MD, ScM, FRCS(C), Stephen F. Hall, MD, MSc, FRCS(C), Marosh Manduch, MD, FRCP(C), Rebecca Griffiths, BSc, Jonathan C. Irish, MD, MSc, FACS, FRCS(C)

Published in: Annals of Surgical Oncology | Issue 5/2019

Login to get access

Abstract

Background

This study aimed to determine the incidence of noninvasive follicular thyroid neoplasm with papillary-like features (NIFTP) in Ontario, Canada and the predictors of disease-free survival (DFS) by comparing patients with follicular variant papillary thyroid cancer (FVPTC) and patients with NIFTP.

Methods

This population-based retrospective cohort study included all patients who had definitive surgery for well-differentiated thyroid cancer (WDTC) in Ontario, Canada between 1990 and 2001 and were followed until 2014. A conservative decision rule was applied to subtype-select FVPTCs into NIFTPs after pathology report review. The primary outcome was DFS, for which Cox proportional hazard regression analysis was performed to assess the impact of FVPTC versus NIFTP.

Results

At pathology re-review of the 725 FVPTC cases, 318 were reclassified as potential NIFTP. The median follow-up time was 15.3 years for the entire cohort and 15.9 years for those alive at the last follow-up visit. Disease failure occurred for 109 patients, 79 (19.4%) in the FVPTC group and 30 (9.4%) in the NIFTP group (p < 0.01). This effect was sustained in the multivariable analysis, with FVPTC showing significantly worse DFS than NIFTP (hazard ratio, 1.84; 95% confidence interval, 1.17–2.89). After recategorization of certain FVPTCs into NIFTPs, the findings showed that NIFTP accounted for 16.8% (1.461/8.699 per 100,000) of all WDTCs.

Conclusion

The disease failure rate for NIFTP was 9.4%. The NIFTP diagnosis is challenging for the pathologist and may make tumor behavior difficult to predict for this entity. Caution should be used in the management of patients with an NIFTP.
Literature
1.
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–7.CrossRefPubMed
2.
Davies L, Welch HG. Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg. 2010;136:440–4.CrossRefPubMed
3.
Kent WD, Hall SF, Isotalo PA, Houlden RL, George RL, Groome PA. Increased incidence of differentiated thyroid carcinoma and detection of subclinical disease. CMAJ. 2007;177:1357–61.CrossRefPubMedPubMedCentral
4.
5.
Nikiforov YE, Seethala RR, Tallini G, et al. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023–9.CrossRefPubMedPubMedCentral
6.
McLaughlin JR, Kreiger N, Marrett LD, Holowaty EJ. Cancer incidence registration and trends in ontario. Eur J Cancer. 1991;27:1520–4.CrossRefPubMed
7.
Hall S, Schulze K, Groome P, Mackillop W, Holowaty E. Using cancer registry data for survival studies: The example of the Ontario Cancer Registry. J Clin Epidemiol. 2006;59:67–76.CrossRefPubMed
8.
Hall SF, Irish JC, Groome PA, Urbach DR. Practice patterns in the management of patients with differentiated thyroid cancer in Ontario Canada 2000–2008. J Otolaryngol Head Neck Surg. 2014;43:29.CrossRefPubMedPubMedCentral
9.
Hall SF, Irish J, Groome P, Griffiths R, Hurlbut D. Do lower-risk thyroid cancer patients who live in regions with more aggressive treatments have better outcomes? Thyroid. 2017;27:1246–57.CrossRefPubMed
10.
Edge S, Byrd D, Compton C, Fritz A, Greene F, Trotti A (eds). AJCC Cancer Staging Manual. 7th ed. Springer, New York. 2010.
11.
Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998;36:8–27.CrossRefPubMed
12.
Lieffers JR, Baracos VE, Winget M, Fassbender K. A comparison of Charlson and Elixhauser comorbidity measures to predict colorectal cancer survival using administrative health data. Cancer. 2011;117:1957–65.CrossRefPubMed
13.
Sharabiani MT, Aylin P, Bottle A. Systematic review of comorbidity indices for administrative data. Med Care. 2012;50:1109–18.CrossRefPubMed
14.
Xu B, Tallini G, Ghossein RA. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: historical context, diagnosis, and future challenges. Endocr Pathol. 2017;28:128–38.CrossRefPubMed
15.
Xu B, Tallini G, Scognamiglio T, Roman BR, Tuttle RM, Ghossein RA. Outcome of large noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Thyroid. 2017;27:512–7.CrossRefPubMedPubMedCentral
16.
Xu B, Farhat N, Barletta JA, et al. Should subcentimeter noninvasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category? Endocrine. 2018;59:143–50.CrossRefPubMed
17.
Lloyd RV, Asa SL, LiVolsi VA, et al. The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Hum Pathol. 2018;74:1–4.CrossRefPubMed
18.
Parente DN, Kluijfhout WP, Bongers PJ, et al. Clinical safety of renaming encapsulated follicular variant of papillary thyroid carcinoma: is NIFTP truly benign? World J Surg. 2018;42:321–6.CrossRefPubMed
19.
Parente DN, Bongers PJ, Verzijl R, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP): trading six for a risky half dozen: Reply. World J Surg. 2018;42:2279.CrossRefPubMed
20.
Cho U, Mete O, Kim MH, Bae JS, Jung CK. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma: the impact of rigid criteria to distinguish noninvasive follicular thyroid neoplasm with papillary-like nuclear features. Mod Pathol. 2017;30:810–25.CrossRefPubMed
21.
Aburjania Z, Jang S, Montemayor-Garcia C, et al. Encapsulated follicular variant of papillary thyroid cancer: are these tumors really benign? J Surg Res. 2017;216:138–42.CrossRefPubMedPubMedCentral
Metadata
Title
A Population-Based Study on NIFTP Incidence and Survival: Is NIFTP Really a “Benign” Disease?
Authors
Antoine Eskander, MD, ScM, FRCS(C)
Stephen F. Hall, MD, MSc, FRCS(C)
Marosh Manduch, MD, FRCP(C)
Rebecca Griffiths, BSc
Jonathan C. Irish, MD, MSc, FACS, FRCS(C)
Publication date
01-05-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07187-0

Other articles of this Issue 5/2019

Annals of Surgical Oncology 5/2019 Go to the issue

Breast Oncology

Prospective Evaluation of Residual Breast Tissue After Skin- or Nipple-Sparing Mastectomy: Results of the SKINI-Trial

Gastrointestinal Oncology

Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy

Pancreatic Tumors

Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery

Breast Oncology

Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come

Breast Oncology

Impact of the SSO-ASTRO Margin Guideline on Rates of Re-excision After Lumpectomy for Breast Cancer: A Meta-analysis

Hepatobiliary Tumors

Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma